This is in line with a study showing that IL-27 pretreatment of hepatocellular carcinoma cells resulted in lowered IL-2 production by anti-CD3/-CD28 activated T-lymphocytes (61). The gene discussed is CD28; the disease is hepatocellular carcinoma.